



Cytokine profiles in overweight and obese subjects and normal weight individuals matched for age and gender

Maryam Azizian¹, Elahe Mahdipour², Seyed Reza Mirhafez³, Sara Shoeibi²,
Mohsen Nematy⁶, Habibollah Esmaily^{5,6}, Gordon AA Ferns⁷ and
Majid Ghayour-Mobarhan^{4,6}

Abstract

Background: Obesity is associated with a state of systemic inflammation, mediated by adipose tissue-derived cytokines that may also have metabolic effects, including an effect on insulin resistance. The aim of this study was to compare the serum profile of pro- and anti-inflammatory cytokines in obese and non-obese subjects.

Methods: A total of 242 subjects who were either overweight or obese (body mass index [BMI] ≥ 25 kg/m²) and non-obese subjects (body mass index <25 kg/m²), were recruited in Mashhad in northeastern Iran. The concentrations of serum interleukin-1 α , -1 β , -2, -4, -6, -8 and -10 (IL-1 α , IL-1 β , IL-2, IL-4, IL-6, IL-8 and IL-10), were measured in all subjects, together with serum vascular endothelial growth factor, interferon- γ , epidermal growth factor, monocyte chemoattractant protein-1 and tumour necrosis factor- α .

Results: The groups differed significantly with respect to measures of adiposity and fasted lipid profile. Serum pro-inflammatory cytokines interferon- γ and interleukin-1 α , and anti-inflammatory cytokines, interleukin-10, and epidermal growth factor were significantly different between obese and non-obese individuals, as was serum high-sensitivity C-reactive protein. Multivariate regression showed that waist circumference was significantly and independently related to serum monocyte chemoattractant protein-1 concentrations ($P = 0.001$).

Conclusion: Despite significant differences in several cytokines between the groups, only monocyte chemoattractant protein-1 appeared to be independently related to a measure of adiposity in this population sample from Iran.

Keywords

Inflammatory cytokines, obese, anthropometric features, lipid profile

Accepted: 5th January 2016

¹Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

²Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

³Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran

⁴Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

⁵Department of Biostatistics, Mashhad University of Medical Sciences, Mashhad, Iran

⁶Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

⁷Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK

Corresponding author:

Majid Ghayour-Mobarhan, Biochemistry and Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 99199-91766 Iran.

Email: ghayourm@mums.ac.ir

Introduction

Obesity is an important public health challenge globally. There are large differences in the prevalence of overweight and obesity regionally.¹ Obesity is a growing problem in both developed and low-income countries.^{2–5} The World Health Organization (WHO) has reported that there are 1 million excess deaths and 12 million life-years of ill health attributable to obesity every year. Sociocultural and environmental factors are determinants of diet and physical activity; consequently, there is a significant difference in the prevalence of obesity between different countries.¹ In Iran, there has been a rapid change in dietary habits and physical activity levels that started during the 1990s and has led to an increased obesity rate among the Iranian people.^{4,6}

Obesity is a common condition that is defined by an excess accumulation of fat in the adipose tissue. It is associated with metabolic, haematological and musculoskeletal complications, including, dyslipidaemia, heart disease, diabetes and increased risk of some malignancies, leading to a shortened life span.^{2,7} Visceral obesity is defined by the presence of excess fat in the abdominal cavity, and is an independent risk factor for several other conditions.⁷

Inflammation arising from within the adipose tissue has been identified as a major source of systemic inflammation and may also be associated with insulin resistance. Adipocytes and adipose tissue-associated macrophages from obese individuals are an important source of inflammatory mediators such as tumour necrosis factor- α (TNF- α), interleukin (IL)-6, IL-1, and monocyte chemoattractant protein-1 (MCP)-1.⁸ It has been proposed that adipokines such as leptin can induce T-helper cells to secrete pro-inflammatory cytokines including TNF- α , and interferon- γ (IFN- γ).^{9,10} IL-1 suppresses adipocyte differentiation and the expression of lipoprotein lipase in adipose tissue. A member of this family, IL-1 α , is involved in the regulation of adipogenesis and energy expenditure.¹¹ Indeed, activation of inflammatory pathways in adipose tissue promotes the release of free fatty acids from triglyceride (TG) stores and results in macrophage infiltration into tissue.⁸ In contrast, decreased concentrations of the anti-inflammatory cytokine, IL-10, have been shown to be associated with obesity and metabolic syndrome. IL-10 inhibits the synthesis of pro-inflammatory cytokines via suppression of NF- κ B in macrophages.¹² A negative relationship between serum IL-10 and body mass index (BMI) has been reported previously.²

Because of the potential importance of cytokine activity in obesity and its related complications, we aimed to compare a panel of pro-inflammatory and anti-inflammatory cytokines in the serum of obese,

overweight and non-obese people living in northeastern Iran.

Methods

Study design and participants

A total of 242 subjects were enrolled into the study. The subjects with obesity were referred to the clinic of Ghaem Hospital, Mashhad for nutritional advice. Using the WHO (BMI) classification,¹³ 77 individuals were classified as non-obese (BMI = 20–24.9 kg/m²), 76 individuals were classified as overweight (BMI = \geq 25–29.9 kg/m²) and 89 individuals were classified as obese (BMI = \geq 30). The control subjects did not have a history of major systemic disease, including renal or infectious disease or lupus. The non-obese, control group, was recruited from the normal population of Mashhad, Iran. We determined the fasting blood glucose (mmol/L) concentrations of each individual in the non-obese group, and this was less than 5.2 mmol/L for each subject. Exclusion criteria included: a history of endocrinological abnormalities, congestive heart disease, liver and/or renal disease, pregnancy and alcohol consumption or treatment with medications that altered blood pressure, glucose or lipid metabolism.

Blood collection and routine biochemistry

Blood samples (10 mL) were obtained in the early morning after an overnight fast. Blood samples were collected into plain VacutainerTM tubes for lipid profile measurements, and into VacutainerTM tubes containing fluoride-oxalate for measurement of fasting blood glucose.

Blood samples were centrifuged and stored at -80°C . Low-density lipoprotein cholesterol, high-density lipoprotein, total cholesterol (TC), cholesterol and glucose were measured using routine techniques using a Cobas Auto Analyser system (ABX Diagnostics, Montpellier, France). Subjects with diabetes or with a serum high-sensitivity C-reactive protein (hsCRP) \geq 95.24 mmol/L were excluded from the study.

The study was approved by the Ethics Committee of the Mashhad University of Medical Sciences, and informed consent was obtained from individuals who were included in the criteria for inclusion.

Measurement of cytokines

Cytokines measurements were performed using Biochip Array Technology on a Randox Evidence Investigator analyser (Randox Laboratories, Belfast, Northern Ireland). The Evidence Investigator Biochip Array Technology was used to perform simultaneous

quantitative detection of multiple analytes using a single patient sample. Intra- and interassay CVs for cytokine markers were $\leq 10\%$.¹⁴ The cytokine array biochip employs a sandwich chemiluminescent immunoassay for a high-throughput measurement of circulating cytokines. The light signal generated from each of the test regions on the biochip is detected using digital imaging technology and compared to that from a stored calibration curve. The serum concentrations of the cytokines were derived from the calibration curve. Serum IL-1 α , IL-1 β , IL-2, IL-4, IL-6, IL-8, IL-10, vascular endothelial growth factor (VEGF), IFN- γ , epidermal growth factor (EGF), MCP-1 and TNF α were determined.

Measurement of baseline data

Demographic data and anthropometric parameters were obtained by using a general questionnaire. Weight was measured using electronic scales when subject with wearing light clothing without shoes. Height was measured using a wall-mounted stadiometer. Blood pressure was measured using a mercury sphygmomanometer according to the standard procedures, and periodical validity and reliability of instrument were checked.

Statistical analyses

Data analyses were performed using the SPSS software (version 16). Comparisons between groups were performed using either t-test or Mann-Whitney U test. Normally distributed data were presented as means \pm standard deviation (SD). Analysis of trends was performed using linear regression models to determine the effect of anthropometric characteristics on serum cytokine and growth factor level. A $P < 0.05$ was considered to be statistically significant.

Results

Participant characteristics associated with evaluation base line data

Table 1 shows data, including anthropometric and biochemical profile of study subjects in the obese and non-obese groups. Unsurprisingly, anthropometric measurements such as weight ($P \leq 0.001$), BMI ($P \leq 0.001$), waist circumference (WC) ($P \leq 0.001$), hip circumference (HC) ($P \leq 0.001$), and fasting blood glucose ($P \leq 0.001$), were significantly different between the groups, when subjects were matched for age and sex. Serum hsCRP was significantly different between the groups ($P \leq 0.001$), and serum fasted TGs ($P = 0.003$) were significantly different between the obese and non-obese groups.

Serum cytokines and growth factor levels

Serum cytokines and growth factors were compared between obese and non-obese groups using Mann-Whitney U test with Bonferroni correction. We found that for the three groups there were significant differences in serum concentrations of IL-10 ($P = 0.012$), IL-1 α ($P = 0.001$) and IFN- γ ($P \leq 0.001$) (Table 2). Serum IL-1 α increased from non-obese group to overweight and obese groups. Serum IL-10 and IFN- γ were highest in the overweight group. Significantly lower concentrations of serum EGF were found in the overweight group compared to non-obese control group. No significant differences were found between the groups for serum IL-2 and IL-6. VEGF though not significant, showed decreased concentrations in the overweight and obese groups compared to non-obese group.

The effect of anthropometric characteristics on cytokine and growth factors

We performed univariate analysis using linear regression models to determine the effect of three anthropometric variables (BMI, WC and HC) on serum cytokine concentrations (Table 3). Univariate analysis showed that WC was associated with serum MCP-1 concentrations. We also examined the effect of WC on the serum concentration of MCP-1 in the presence of potentially confounding factors such as sex, age (while already being matched between groups; their distribution in the subgroups differed between groups), TC, TG, high-density lipoprotein cholesterol (HDL-C), diastolic blood pressure (DBP) and hsCRP using multivariate analysis. We found that WC remained positively associated with serum MCP-1 concentration even after correction for these confounding variables.

Discussion

As for several previous studies,^{15,16} we found that in addition to age, gender and blood pressure, several biochemical parameters, including, blood glucose and TGs were associated with degrees of adiposity. Cytokines are mediators of pro- and anti-inflammatory responses. We found that among our panel of pro/anti-inflammatory cytokines and growth factors, IL-10, IFN- γ and IL-1 α were significantly ($P < 0.05$) different between non-obese, overweight and obese people. We observed an incremental trend in the serum concentrations of these cytokines from non-obese to obese groups. We also showed that serum EGF concentrations were significantly lower in overweight people compared to the non-obese controls. Previous reports have also shown that people with obesity have a higher concentration of serum IL-10, IFN- γ , TNF- α , and IL-12, and that high

Table 1. Base line demographic, anthropometric and biochemical data of subjects in each group.

	Non-obese (n = 77)	Overweight (n = 76)	Obese (n = 89)	P	P1	P2	P3
Age (year) (Mean ± SD)	51.6 ± 11.9	50.1 ± 11.4	51.1 ± 8.0	0.644			
Sex (no. (%))							
Male	42 (54.5)	34 (44.7)	35 (39.3)	0.142			
Female	35 (45.5)	42 (55.3)	54 (60.7)				
Smoking (no. (%))							
Yes	18 (26.5)	21 (31.3)	21 (31.3)	0.774			
No	50 (73.5)	46 (68.7)	46 (68.7)				
Height (m) (mean ± SD)	1.6 ± 0.09	1.6 ± 0.08	1.6 ± 0.08	0.272			
Weight (kg) (mean ± SD)	60.8 ± 9.1	72.1 ± 8.4	86.2 ± 13.3	<0.001	<0.001	<0.001	<0.001
BMI (kg/m ²) (mean ± SD)	22.8 ± 1.9	27.6 ± 1.6	33.5 ± 3.4	<0.001	<0.001	<0.001	<0.001
WC (m) (mean ± SD)	0.87 ± 0.10	0.97 ± 0.07	1.07 ± 0.11	<0.001	<0.001	<0.001	<0.001
HC (m) (mean ± SD)	0.96 ± 0.07	1.04 ± 0.04	1.14 ± 0.09	<0.001	<0.001	<0.001	<0.001
SBP (kPa) (mean ± SD)	16.2 ± 3.0	16.4 ± 3.3	17.2 ± 2.9	0.109			
DBP (kPa) (mean ± SD)	10.6 ± 1.5	10.6 ± 1.9	11.6 ± 1.7	<0.001	0.999	0.002	0.001
FBG (mmol/L) (mean ± SD)	4.6 ± 0.6	5.0 ± 0.8	4.9 ± 0.8	0.001	0.003	0.007	0.931
TC (mmol/L) (mean ± SD)	4.8 ± 0.9	5.0 ± 1.0	5.0 ± 1.0	0.252			
TG (mmol/L) (median(IQR))	1.2 (1.0–1.6)	1.6 (1.1–2.2)	1.5 (1.1–2.2)	0.003	0.003	0.024	0.703
HDL-C (mmol/L) (mean ± SD)	1.1 ± 0.2	1.0 ± 0.2	1.1 ± 0.2	0.261			
LDL-C (mmol/L) (mean ± SD)	2.9 ± 0.7	3.2 ± 0.7	3.0 ± 0.8	0.28			
hsCRP (mmol/L) (median(IQR))	14.2 (11.9–28.5)	22.8 (10.4–53.3)	37.1 (19.0–57.1)	<0.001	0.022	<0.001	0.294

Note: Comparisons were performed by one-way ANOVA and Kruskal–Wallis test for normally and non-normally distributed variables, respectively. Also the Tukey/Dunnnett's T3 test and Mann–Whitney U test were used for comparison between groups.

Values are presented as mean ± SD, median and interquartile range for normally and non-normally distributed variables, respectively.

P1: comparison between non-obese and overweight, P2: comparison between non-obese and obese, P3: comparison between overweight and obese; BMI: body mass index; WC: waist circumference; HC: hip circumference; FBG: fasting blood glucose; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; IQR: interquartile range; hsCRP: high-sensitivity CRP.

concentrations of IL-4, IL-10 and IL-13 are related to low physical activity in obese people.¹⁷ A further study has reported a high concentration of IL-10 in obese people, but that the metabolic syndrome was not associated with low concentrations of IL-10.¹⁸ A study in young adolescents in Taiwan has reported low concentration of serum IL-10 and high concentrations of serum IL-1 β in overweight and obese subjects. The authors also reported a negative correlation of IL-10 with IL-1 β cytokines in obesity.¹² In a further study on the association of inflammatory cytokines in obese and non-obese women, it was observed that the concentration of serum TNF- α , IL-6, P-selectin, intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) was higher in obese women, and that weight loss reduced the concentrations of these cytokines in the obese group.¹⁹ For other cytokines and growth factors including IL-2, IL-4, IL-6, IL-8, VEGF, TNF- α , IL-1 β and MCP-1, we did not observe a significant ($P < 0.05$) differences between our groups. We found a high variation in serum cytokine concentrations within each

group, highlighting the dependency of the circulatory cytokine concentrations to various conditions.

Although there have been previous reports of high concentrations of IL-1, IL-18, IL-8 and IL-6 in obese people,^{20–22} we did not find any significant differences in serum IL-6 and IL-8 between our groups.

VEGF did not differ significantly between the groups. The overexpression of VEGF in white and brown adipose tissue has been shown to protect the animals against high-fat diet-induced hypoxia and obesity.²³ IL-4 is another important cytokine involved in adipogenesis inhibition and lipolysis enhancement.²⁴ An increased concentration of IL-4 has been reported in girls with central obesity.²⁵ In present study, we observed a statistically non-significant difference in IL-4 concentration from non-obese to obese group.

We performed a univariate analysis to evaluate the effects of three anthropometric variables (BMI, WC and HC) on serum cytokine concentrations. As data in Table 3 show, there was an independent negative relationship between WC and serum MCP-1 concentrations. WC which in contrast to BMI is independent of age²⁶

Table 2. Comparison of serum cytokine and growth factor concentrations in groups of individuals with different degrees of adiposity.

Serum cytokines and growth factors	Non-obese (n = 77)	Overweight (n = 76)	Obese (n = 89)	P	P1	P2	P3
IL-2	2.7 (2.5–3.1)	2.7 (2.5–3.2)	2.7 (2.5–3.4)	0.900			
IL-4	1.8 (1.6–2.4)	2.2 (1.8–2.6)	2.0 (1.7–2.6)	0.071			
IL-6	1.2 (0.7–1.3)	0.9 (0.6–1.6)	0.9 (0.6–1.6)	0.987			
IL-8	8.4 (4.6–17.8)	5.8 (3.3–9.4)	5.9 (3.2–10.6)	0.049	0.028	0.049	0.953
IL-10	0.82 (0.67–1.00)	0.89 (0.76–1.23)	0.80 (0.63–1.24)	0.012	0.015	0.012	0.007
VEGF	115.6 (71.1–117.1)	71.1 (27.3–119.5)	75.0 (21.3–153.6)	0.287			
IFN- γ	0.57 (0.41–0.67)	0.68 (0.56–1.58)	0.57 (0.00–0.72)	<0.001	<0.001	<0.001	0.002
TNF α	1.6 (1.2–2.1)	1.8 (1.2–2.2)	1.8 (1.4–2.2)	0.166			
IL-1 α	0.53 (0.49–0.61)	0.58 (0.51–0.66)	0.61 (0.51–0.76)	0.001	0.008	0.001	0.240
IL-1 β	104.0 (56.6–191.4)	80.8 (46.4–158.9)	107.2 (44.4–181.3)	0.071			
MCP-1	104.0 (56.6–191.4)	80.8 (46.4–158.9)	107.2 (44.4–181.3)	0.386			
EGF	51.3 (6.3–135.5)	24.4 (3.3–89.2)	38.6 (11.8–136.6)	0.034	0.012	0.034	0.052

Note: Values are expressed as median (Interquartile range).

The SI unit values are ng/L for all cytokines.

Comparisons were performed by Kruskal–Wallis H test and post hoc of Mann–Whitney U test. Bonferroni correction was performed (significant level: $P < 0.05$).

P1: comparison between non-obese and overweight, P2: comparison between non-obese and obese, P3: comparison between overweight and obese; GF: growth factors; EGF: epidermal growth factor; IFN- γ : interferon γ ; IL-1 α : interleukin-1 α ; IL-1 β : interleukin-1 β ; IL-2: interleukin-2; IL-4: interleukin-4; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; MCP-1: monocyte chemoattractant protein; TNF α : tumour necrosis factor; VEGF: vascular endothelial growth factor.

Table 3. Association of anthropometrics variables and serum cytokines and growth factors using linear regression models.

		Univariate					Univariate				
		\hat{a}	CI	P			\hat{a}	CI	P		
IL-2	BMI	0.011	–0.50	0.72	0.524	EGF	BMI	1.793	–1.377	4.964	0.266
	WC	0.010	–0.15	0.34	0.432		WC	1.118	–0.151	2.386	0.084
	HC	0.021	–0.009	0.050	0.176		HC	0.389	–1.169	1.946	0.623
IL-6	BMI	0.028	–0.61	0.117	0.534	IL8	BMI	0.547	–0.405	1.498	0.259
	WC	0.014	–0.21	0.050	0.428		WC	0.256	–0.121	0.633	0.183
	HC	0.005	–0.38	0.048	0.819		HC	–0.057	–0.520	0.406	0.809
IL-10	BMI	0.010	–0.28	0.047	0.608	VEGF	BMI	1.081	–1.198	3.359	0.351
	WC	0.008	–0.007	0.023	0.308		WC	0.053	–0.863	0.969	0.910
	HC	0.009	–0.010	0.027	0.362		HC	–0.023	–1.141	1.096	0.968
IFN- γ	BMI	0.014	–0.026	0.054	0.499	TNF α	BMI	0.034	–0.014	0.082	0.168
	WC	0.011	–0.005	0.028	0.167		WC	0.015	–0.004	0.035	0.123
	HC	0.006	–0.014	0.026	0.578		HC	0.014	–0.010	0.037	0.260
IL-1 α	BMI	0.005	–0.003	0.013	0.190	IL1 β	BMI	0.007	–0.005	0.018	0.245
	WC	0.002	–0.001	0.005	0.184		WC	0.004	<0.001	0.009	0.062
	HC	0.002	–0.002	0.006	0.305		HC	0.005	–0.001	0.010	0.079
MCP-1	BMI	–7.070	–2.948	1.409	0.487	IL4	BMI	0.023	–0.019	0.065	0.283
	WC	–1.459	–2.323	–0.595	0.001		WC	0.015	–0.002	0.031	0.092
	HC	–0.087	–1.162	0.989	0.874		HC	0.006	–0.015	0.027	0.552
Multivariate ^a											
MCP-1	WC	–1.789	–2.904	–0.675	0.002						

^aIn present of age, sex, smoking, TC, TG, HDL-C, DBP and hsCRP.

β : coefficient regression, CI: confidence interval, BMI: body mass index, WC: waist circumference, HC: hip circumference, EGF: epidermal growth factor, IFN- γ : interferon γ , IL-1 α : interleukin-1 α , IL1 β : interleukin-1 β , IL-2: interleukin-2; IL-4: interleukin-4; IL-6: interleukin-6; IL-8: interleukin-8; IL-10: interleukin-10; MCP-1: monocyte chemoattractant protein; TNF α : tumour necrosis factor; VEGF: vascular endothelial growth factor.

showed a significant independent association with serum MCP-1 when this was evaluated after correction for confounding factors. Several studies have identified a strong association between plasma MCP-1 concentrations and body weight.^{27–29} An increase in MCP-1 expression by adipose tissue may affect macrophage infiltration into this tissue, causing an enhancement of the inflammatory state in obesity.^{28,30}

In summary, we have found a complex relationship between adiposity and serum cytokine and growth factor profile. However, there was a consistent and independent relationship between adiposity and serum MCP-1 concentrations. Serum MCP-1 may enhance the pro-inflammatory milieu by increasing macrophage infiltration of adipose tissue.

Acknowledgements

This work was conducted as a MSc degree thesis (thesis number: A450) with financial support provided by the Research Council at the Mashhad University of Medical Sciences, Mashhad, Iran.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This work was supported by the Research Council at the Mashhad University of Medical Sciences, Mashhad, Iran.

Ethical approval (including reference number)

The study was approved by the Ethics Committee of the Mashhad University of Medical Sciences (REC Number: 938052) and informed consent was obtained from individuals who were included in the criteria for inclusion.

Guarantor

Mashhad University of Medical Sciences.

Contributorship

Majid Ghayour-Mobarhan was involved in protocol development, gaining ethical approval, patient recruitment and data analysis. Elahe Mahdipour was involved in developing and conducting the laboratory experiments and the manuscript revision. Maryam Azizian and Seyed Reza Mirhafez have done the experiments and the statistical analysis. Sara Shoeibi wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

References

- Katz DL, O'Connell M, Yeh M-C, et al. Public health strategies for preventing and controlling overweight and obesity in school and worksite settings: A report on recommendations of the Task Force on Community Preventive Services. *MMWR Morb Mortal Wkly Rep* 2005; 7: 1–12.
- Arslan N, Erdur B and Aydin A. Hormones and cytokines in childhood obesity. *Indian Pediatr* 2010; 47: 829–839.
- Bahrami H, Sadatsafavi M, Pourshams A, et al. Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. *BMC Public Health* 2006; 6: 1–9.
- Mirzazadeh A, Sadeghirad B, Haghdost AA, et al. The prevalence of obesity in iranin recent decade; a systematic review and meta-analysis study. *Iranian J Public Health* 2009; 38: 1–11.
- Veghari G, Sedaghat M, Joshaghani H, et al. The prevalence and associated factors of central obesity in Northern Iran. *ICRJ* 2010; 4: 146–168.
- Dorosty AR, Siassi F and Reilly JJ. Obesity in Iranian children. *Arch Dis Child* 2002; 87: 388–391.
- Malekzadeh R, Mohamadnejad M, Merat S, et al. Obesity pandemic: an Iranian perspective. *Arch Iranian Med* 2005; 8: 1–7.
- Hsieh PS. Obesity-induced adipose tissue inflammation and insulin resistance. In: Croniger C (ed.) *Role of the adipocyte in development of type 2 diabetes*. Europe: InTech, 2011, pp.197–214.
- Hajer GR, van Haeften TW and Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. *Eur Heart J* 2008; 29: 2959–2971.
- Pacifico L, Di Renzo L, Anania C, et al. Increased T-helper interferon-gamma-secreting cells in obese children. *Eur J Endocrinol* 2006; 154: 691–697.
- Manchanda PK, Bid HK, Achyut BR, et al. Interleukin-1 receptor antagonist gene polymorphism and obesity: a pilot study from north india. *Indian J Clin Biochem* 2007; 22: 61–64.
- Chang JS, Chang CC, Chien EY, et al. Association between interleukin 1 β and interleukin 10 concentrations: a cross-sectional study in young adolescents in Taiwan. *BMC Pediatr* 2013; 13: 1–10.
- World Health Organization. BMI classification. Available at: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html (accessed 15 February 2014).
- FitzGerald SP, Lamont JV, McConnell RI, et al. Development of a high-throughput automated analyzer using biochip array technology. *Clin Chem* 2005; 51: 1165–1176.
- Li YM, Fu CC and Yeh JI. Overweight and clustering of cardiovascular risk factors among freshmen at a national university in Hualien county. *Tzu Chi Med J* 2005; 17: 323–329.
- Chu NP, Rimm EB, Wang DJ, et al. Clustering of cardiovascular disease risk factors among obese schoolchildren: the Taipei Children Heart Study. *Am J Clin Nutr* 1998; 67: 1141–1146.
- Schmidt FM, Weschenfelder J, Sander C, et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. *PLoS One* 2015; 10: e0121971.
- Calcaterra V, Amici MD, Klersy C, et al. Adiponectin, IL-10 and metabolic syndrome in obese children and adolescents. *Acta Biomed* 2009; 80: 117–123.
- Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. *Circulation* 2002; 105: 804–809.
- Osborn O, Gram H, Zorrilla EP, et al. Insights into the roles of the inflammatory mediators IL-1, IL-18 and PGE2 in obesity and insulin resistance. *Swiss Med Wkly* 2008; 138: 665–673.
- Straczkowski M, Dzienis-Straczkowska S, Stepień A, et al. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor- α system. *J Clin Endocrinol Metab* 2002; 87: 4602–4606.
- Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Physiol Endocrinol Metab* 2001; 280: 745–751.
- Elias I, Franckhauser S, Ferré T, et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. *Diabetes* 2012; 61: 1801–1813.
- Tsao C-H, Shiao M-Y, Chuang P-H, et al. nterleukin-4 regulates lipid metabolism by inhibiting adipogenesis and promoting lipolysis. *Lipid Res* 2014; 55: 385–397.
- El-Wakkada A, El-Morsi Hassan N, Sibaii H, et al. Proinflammatory, anti-inflammatory cytokines and adiponkines in students with central obesity. *Cytokine* 2013; 61: 682–687.
- Warren TY, Wilcox S, Dowda M, et al. Independent association of waist circumference with hypertension and diabetes in African American Women, South Carolina, 2007–2009. *Prev Chronic Dis* 2012; 9: E105.
- Takahashi K, Mizuarai S, Araki H, et al. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. *J Biol Chem* 2003; 278: 46654–46660.
- Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *J Clin Invest* 2006; 116: 1494–1505.
- Sartipy P and Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. *Proc Natl Acad Sci U S A* 2003; 100: 7265–7270.
- Oh DY, Morinaga H, Talukdar S, et al. Increased macrophage migration into adipose tissue in obese mice. *Diabetes* 2012; 61: 346–354.